Alexander Nast, Andreas Altenburg, Matthias Augustin, Frank Bachmann, Wolf‐Henning Boehncke, Markus Cornberg, Hilte Geerdes‐Fenge, Brit Häcker, Peter Härle, Joachim Klaus, Michaela Köhm, Arno Köllner, Ulrich Mrowietz, Hans‐Michael Ockenfels, Antonia Pennitz, Sandra Philipp, Thomas Richter, Thomas Rosenbach, Tom Schaberg, Martin Schlaeger, Gerhard Schmid‐Ott, Michael Sebastian, Karisa Thölken, Ralph von Kiedrowski, Uwe Willuhn, Christoph Zeyen
- The present Part 2 of the updated German S3 guideline on the treatment of psoriasis vulgaris provides recommendations for therapy selection in special clinical situations and in the presence of comorbidities. A major focus of this update is the chapter on screening for tuberculosis as well as therapy selection and management in latent tuberculosis. The recommendations regarding the use of interferon-gamma release assays and the indication for chest radiography have been extensively revised. In addition, the guidance on the suitability of systemic psoriasis therapies in patients with latent tuberculosis and on the need for preventive antituberculous treatment has been thoroughly updated. In the chapter on inflammatory bowel diseases, risankizumab and guselkumab have been added as recommended treatment options, as both agents have recently been approved for the indications Crohn's disease and ulcerative colitis. Further substantial revisions are included in the chapters on patients withThe present Part 2 of the updated German S3 guideline on the treatment of psoriasis vulgaris provides recommendations for therapy selection in special clinical situations and in the presence of comorbidities. A major focus of this update is the chapter on screening for tuberculosis as well as therapy selection and management in latent tuberculosis. The recommendations regarding the use of interferon-gamma release assays and the indication for chest radiography have been extensively revised. In addition, the guidance on the suitability of systemic psoriasis therapies in patients with latent tuberculosis and on the need for preventive antituberculous treatment has been thoroughly updated. In the chapter on inflammatory bowel diseases, risankizumab and guselkumab have been added as recommended treatment options, as both agents have recently been approved for the indications Crohn's disease and ulcerative colitis. Further substantial revisions are included in the chapters on patients with a history of malignancy and viral hepatitis.…
